ID: ALA3794291

Max Phase: Preclinical

Molecular Formula: C19H13N3O2S

Molecular Weight: 347.40

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(O)c1cccc(Nc2ncnc3sc(-c4ccccc4)cc23)c1

Standard InChI:  InChI=1S/C19H13N3O2S/c23-19(24)13-7-4-8-14(9-13)22-17-15-10-16(12-5-2-1-3-6-12)25-18(15)21-11-20-17/h1-11H,(H,23,24)(H,20,21,22)

Standard InChI Key:  HKDXQXQGYQOLOD-UHFFFAOYSA-N

Associated Targets(Human)

Casein kinase II 1406 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 347.40Molecular Weight (Monoisotopic): 347.0728AlogP: 4.80#Rotatable Bonds: 4
Polar Surface Area: 75.11Molecular Species: ACIDHBA: 5HBD: 2
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 4.75CX Basic pKa: 3.13CX LogP: 4.50CX LogD: 2.03
Aromatic Rings: 4Heavy Atoms: 25QED Weighted: 0.55Np Likeness Score: -1.46

References

1. Ostrynska OV, Balanda AO, Bdzhola VG, Golub AG, Kotey IM, Kukharenko OP, Gryshchenko AA, Briukhovetska NV, Yarmoluk SM..  (2016)  Design and synthesis of novel protein kinase CK2 inhibitors on the base of 4-aminothieno[2,3-d]pyrimidines.,  115  [PMID:27017545] [10.1016/j.ejmech.2016.03.004]

Source